Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is planned to compare Letrozole SIE with Femara, both in combination with ribociclib, in postmenopausal women with HR-positive, HER2-negative, i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)
• Letrozole SIE (letrozole)
• Ribociclib (ribociclib)

Snippet

Sponsor: Rovi Pharmaceuticals Laboratories | Conditions: Advanced, Metastatic Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING